SAN DIEGO — The investigative oral Bruton's tyrosine kinase (BTK) inhibitor remibrutinib shows promise in patients with moderate to severe hidradenitis suppurativa (HS), results from a randomized 16-week phase 2 trial showed. "Research shows that the TNF-alpha and IL-17 signaling pathways have important roles in HS," lead investigator Alexa B. Kimball, MD, MPH , from the Clinical Laboratory for Epidemiology and Applied Research in Skin at Beth Israel Deaconess Medical Center, Boston, ...